Timothy A. Yap, MD, PhD, on New Findings on Treating Solid Tumors With PARP and ATR Inhibitors
AACR Annual Meeting 2023
Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in patients with solid tumors harboring DNA damage response alterations. The findings showed that low-dose intermittent regimens of camonsertib and different PARP inhibitor combinations were safe. In addition, anticancer activity was observed in patients with platinum- and PARP inhibitor–resistant tumors. Patients with late-line ovarian cancer derived the most benefit from therapy. (Abstract CT018)
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We now have four FDA-approved PARP inhibitors for various indications in patients with different cancers. This has really made a huge difference to patients lives. However, even in the most sensitive of patients, for example, patients with BRCA 1 and BRCA 2 mutated cancers, not all patients will respond. In addition to that, even in patients who respond, the chances of resistance coming in, leading to resistance and disease progression is still a near inevitable consequence, and therefore we really need better treatment options for patients. And a rational approach is really to try and develop combinations that make sense to the biology of the cancer as it evolves over time.
So, with that in mind, in this clinical trial that I presented, we combined the ATR inhibitor camonsertib with three different PARP inhibitors, olaparib, talazoparib, and niraparib, to try and optimize the use of this combination in terms of a therapeutic window that is well tolerated, but would also lead to efficacy. In the past, the concomitant combinations of high doses of these drugs has led to overwhelming toxicities in patients because of overlapping toxicities, including myelosuppression, fatigue and GI symptoms. So, on this clinical trial, we use low dose intermittent regimens of the ATR inhibitor, camonsertib, and the three different PARP inhibitors in combination.
And we found that this was safe and well-tolerated in patients. There were hematological events observed, but these were transient and reversible with dose interruptions. No prophylactic growth factors were required on trial. Importantly, antitumor activity was observed in patients with platinum and PARP inhibitor resistant tumors with predefined DDR genomic alterations. And the durable antitumor activity was encouraging with a clinical benefit rate of 48% in the efficacy population of 90 patients. And in patients with late-line ovarian cancer, which is a real area of clinical unmet need, they derive the most benefit from therapy with an overall response of 32%, a clinical benefit rate of 58%, and a median progression-free survival of approximately seven months, which really compares favorably to current therapeutic options for patients.
The molecular response rate as well was 66% in 47 evaluable patients, really supporting the antitumor activity of the combinations. Currently, dose optimization to refine a tailored [inaudible 00:03:03] dose and tumor-specific expansions is ongoing in this clinical trial. But this approach could certainly represent a novel strategy and patients who have great unmet need and really truly represents an area of unmet clinical need.
Related Videos
The ASCO Post Staff
Pierce K.H. Chow, PhD, MBBS, of the National Cancer Centre, Singapore and Duke-NUS Medical School, discusses phase III findings showing that, for patients with hepatocellular carcinoma at high risk of disease recurrence, adjuvant therapy with atezolizumab plus bevacizumab after resection or thermal ablation was more effective than active surveillance. According to Dr. Chow, these results could lead to reassessment of surgical resection in this disease. (Abstract CT003)
The ASCO Post Staff
R. Katie Kelley, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses phase III findings of the KEYNOTE-966 study, which showed that adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer. (Abstract CT008)
The ASCO Post Staff
Lindsay L. Peterson, MD, of the Washington University, St. Louis, discusses the value of physical activity in improving cancer prognosis, especially for patients with breast or colon cancer. Aerobic exercises and resistance training are recommended during and after treatment. Exercise may help inhibit tumor growth, improve quality of life by decreasing fatigue and anxiety, build muscle mass, increase physical function, and reduce surgical complications and treatment delays.
The ASCO Post Staff
Karriem S. Watson, DHSc, MPH, of the National Institutes of Health All of Us Research Program, discusses the importance of engaging in clinical trials for those who are underrepresented in biomedical research. Community engagement is a proven and effective tool, Dr. Watson says, to enhance participation in research by increasing access to and awareness of medical studies and has already been shown to expand the reach of therapies, improving cancer outcomes. (Abstract PL03-05)
The ASCO Post Staff
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a poor prognosis. This result suggests the need to develop new management strategies for patients with early-stage breast cancer. (Abstract LB119)
